{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:16:54Z","timestamp":1791274614755,"version":"4.1.0"},"reference-count":94,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,4,6]],"date-time":"2001-04-06T00:00:00Z","timestamp":986515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microscopy Res &amp;amp; Technique"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite considerable research into the pathogenesis of idiopathic headaches, such as migraine, the pathophysiological mechanisms underlying them remain poorly understood. Although it is well established that the trigeminal nerve becomes activated during migraine, the consequences of this activation remain controversial. One theory, based on preclinical observations, is that activation of trigeminal sensory fibers leads to a painful neurogenic inflammation within the meningeal (dural) vasculature mediated by neuropeptide release from trigeminal sensory fibres and characterized by plasma protein extravasation, vasodilation, and mast cell degranulation. Effective antimigraine agents such as ergots, triptans, opioids, and valproate inhibit preclinical neurogenic dural extravasation, suggesting that this activity may be a predictor of potential clinical efficacy of novel agents. However, several clinical trials with other agents that inhibit this process preclinically have failed to show efficacy in the acute treatment of migraine in man. Alternatively, it has been proposed that painful neurogenic vasodilation of meningeal blood vessels could be a key component of the inflammatory process during migraine headache. This view is supported by the observation that jugular plasma levels of the potent vasodilator, calcitonin gene\u2010related peptide (CGRP) are elevated during the headache and normalized by successful sumatriptan treatment. Preclinically, activation of trigeminal sensory fibers evokes a CGRP\u2010mediated neurogenic dural vasodilation, which is blocked by dihydroergotamine, triptans, and opioids but unaffected by NK<jats:sub>1<\/jats:sub> receptor antagonists that failed in clinical trials. These observations suggest that CGRP release with associated neurogenic dural vasodilation may be important in the generation of migraine pain, a theory that would ultimately be tested by the clinical testing of a CGRP receptor antagonist. Microsc. Res. Tech. 53:167\u2013178, 2001. \u00a9 2001 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jemt.1081","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T16:21:39Z","timestamp":1030292499000},"page":"167-178","source":"Crossref","is-referenced-by-count":191,"title":["Neurogenic inflammation in the context of migraine"],"prefix":"10.1002","volume":"53","author":[{"given":"David J.","family":"Williamson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Hargreaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,4,6]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.1998.1809644.x"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(90)90112-L"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00080-5"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00541-6"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(95)00106-9"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(92)90017-P"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb14679.x"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1991.1104165.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90719-X"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(91)90165-8"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(10)80017-4"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00228731"},{"key":"e_1_2_1_14_1","unstructured":"ConnorHE BertinL GilliesS BeattieD WardP1998.Clinical evaluation of a novel potent CNS penetrating NK1receptor antagonists in the acute treatment of migraineIn: Abstracts of the 12th Migraine Trust Symposium 1\u20134 September1998 London."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1997.3709590.x"},{"key":"e_1_2_1_16_1","first-page":"268","article-title":"A study of safety and efficacy in patients with acute migraine using PNU\u2010142633, a selective 5\u2010HT1D agonist","volume":"20","author":"Cutler NR","year":"2000","journal-title":"Cephalalgia"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb15124.x"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00032-5"},{"key":"e_1_2_1_19_1","unstructured":"DienerHC.1995. For theRPR100893\u2010201 migraine study group.Substance\u2010P antagonist RPR100893\u2010201 is not effective in human migraine attacks. 6th International Headache Research Seminar November 17\u201319 Copenhagen Denmark."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199511000-00008"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/82.2.274"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(91)90253-K"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703110"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1987.126"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(98)00066-7"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)01247-F"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00367-T"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90005-A"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550010-00010"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199401040-00002"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230214"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1707785.x"},{"key":"e_1_2_1_35_1","first-page":"318","article-title":"Migraine treatment with the selective 5\u2010HT1F receptor agonist (SSOFRA) LY334370","volume":"19","author":"Goldstein DJ","year":"1999","journal-title":"Cephalalgia"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1938.02270040093005"},{"key":"e_1_2_1_37_1","first-page":"367","article-title":"Safety, pharmacokinetics and preliminary efficacy data of LY334370, a novel SSOFRA, in patients with acute migraine","volume":"19","author":"Granier LA","year":"1999","journal-title":"Cephalalgia"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-3623(97)00078-5"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(91)90630-B"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(92)90084-G"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199707070-00029"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1993.hed3310541.x"},{"key":"e_1_2_1_43_1","first-page":"283","article-title":"Cyclooxygenase (COX\u20101) inhibition with ketorolac blocks central trigeminal transmission but not CGRP\u2010release from peripheral trigeminal sensory neurons","volume":"20","author":"Kaube H","year":"2000","journal-title":"Cephalagia"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1963.hed0303112.x"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb13361.x"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90591-A"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16388.x"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(85)90027-7"},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1996.3601053.x"},{"issue":"1","key":"e_1_2_1_50_1","first-page":"S33","article-title":"Ergotamine tartrate and dihydroergotamine mesylate: safety profiles","volume":"37","author":"Lipton RB","year":"1997","journal-title":"Headache"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1708833.x"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.07-12-04129.1987"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90798-9"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(96)03137-5"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/121.7.1231"},{"key":"e_1_2_1_56_1","unstructured":"McCall R.B.1999.Preclinical and clinical studies in migraine using the selective 5\u2010HT1Dreceptor agonist PNU\u2010142633. Presented at IBC Migraine Conference Philadelphia April1999."},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(90)90169-5"},{"key":"e_1_2_1_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80516-1"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01072-8"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410160202"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(92)90097-P"},{"key":"e_1_2_1_62_1","first-page":"159","article-title":"Neurovascular and molecular mechanisms in migraine headaches","volume":"5","author":"Moskowitz MA","year":"1993","journal-title":"Cerebrovasc Brain Metab Rev"},{"key":"e_1_2_1_63_1","unstructured":"NissilaM ParkkolaR SonninenP SalonenR.1996.Intracerebral arteries and gadolinium enhancement in migraine without aura. In: Abstracts of the 11th Migraine Trust International Symposium 9\u201312th September 1996 London."},{"key":"e_1_2_1_64_1","unstructured":"NormanB PanebiancoD BlockG.1998.A placebo\u2010controlled in\u2010clinic study to explore the safety and efficacy of intravenous L\u2010758 298 (a pro\u2010drug of the NK1receptor antagonist L\u2010754 030) in the acute treatment of migraine. In: Abstracts of the 12th Migraine Trust Symposium 1\u20134 September London."},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.08-07-02468.1988"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)00668-W"},{"key":"e_1_2_1_67_1","first-page":"1","article-title":"Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications","volume":"3","author":"Olesen J","year":"1991","journal-title":"Cerebrovasc Brain Metab Rev"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410090406"},{"issue":"2","key":"e_1_2_1_69_1","first-page":"A274","article-title":"Imaging neurogenic inflammation in patients with migraine headaches","volume":"52","author":"Pappagallo M","year":"1999","journal-title":"Neurology"},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1990.hed30s1005.x"},{"key":"e_1_2_1_71_1","first-page":"23","volume-title":"Oral administration of the selective 5\u2010HT1F receptor agonist LY334370 inhibits trigeminal stimulation\u2010induced fos protein expression in the second order nociceptive neurones in the rat brainstem","author":"Phebus LA","year":"1998"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00885-0"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)00728-3"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702532"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1940.01210040002001"},{"key":"e_1_2_1_76_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3666"},{"key":"e_1_2_1_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200002)47:2<238::AID-ANA15>3.0.CO;2-L"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410240607"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13432.x"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(97)00057-9"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1999.1910851.x"},{"issue":"7","key":"e_1_2_1_82_1","first-page":"S6","article-title":"Overview of diagnosis and treatment of migraine","volume":"44","author":"Silberstein SD","year":"1994","journal-title":"Neurology"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(89)90385-0"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1995.015002109.x"},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1997.3710635.x"},{"key":"e_1_2_1_86_1","first-page":"230","article-title":"Neuropeptides in the cerebral circulation","volume":"1","author":"Uddman R","year":"1989","journal-title":"Cerebrovasc Brain Metab Rev"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1838(89)90109-4"},{"key":"e_1_2_1_88_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1704518.x"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1704525.x"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)83028-2"},{"key":"e_1_2_1_91_1","first-page":"346","article-title":"Prejunctional modulation of dural neurogenic vasodilation in the rat","volume":"19","author":"Williamson DJ","year":"1999","journal-title":"Cephalalgia"},{"key":"e_1_2_1_92_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550020092020"},{"key":"e_1_2_1_93_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0026-895X(25)09047-9","article-title":"5\u2010Carboxamido\u2010tryptamine, CP\u2010122,288 and dihydroergotamine but not sumatriptan, CP\u201093,129, and serotonin\u20105\u2010O\u2010carboxymethyl\u2010glycyl\u2010tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5\u2010hydroxytryptamine1B receptors","volume":"49","author":"Yu XJ","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_94_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1992.1201029.x"},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.24.9.1335"}],"container-title":["Microscopy Research and Technique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjemt.1081","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jemt.1081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:07:15Z","timestamp":1760641635000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jemt.1081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,6]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1002\/jemt.1081"],"URL":"https:\/\/doi.org\/10.1002\/jemt.1081","archive":["Portico"],"relation":{},"ISSN":["1059-910X","1097-0029"],"issn-type":[{"value":"1059-910X","type":"print"},{"value":"1097-0029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4,6]]}}}